Esther H. Chang

11.9k citations

124 papers · 9.6k indexed · 3 hit papers · h-index 51

Oncology top 0.5%
- Cancer-related Molecular Pathways 27
Cancer Research top 1%
- MicroRNA in disease regulation 9
Biomaterials top 0.5%
- Nanoparticle-Based Drug Delivery 10
Molecular Biology top 1%
- RNA Interference and Gene Delivery 35
- Advanced biosensing and bioanalysis techniques 14
- DNA and Nucleic Acid Chemistry 8
Biotechnology top 0.5%
- Cancer Research and Treatments 17
Genetics
- Virus-based gene therapy research 24

Co-authors: Kathleen F. Pirollo Douglas R. Lowy Edward M. Scolnick Antonina Rait Shiv Srivastava Zhiqiang Zou William A. Blattner Robert A. Weinberg
Cited by: Oncology Cancer Research Biomaterials
Journals: Nature (6 papers)Science (2 papers)Proceedings of the National Academy of Sciences (4 papers)
Partner nations: United States Japan Netherlands

In The Last Decade

Esther H. Chang

124 papers receiving 8.8k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Esther H. Chang

Since Specialization

Citations

This map shows the geographic impact of Esther H. Chang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Esther H. Chang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Esther H. Chang more than expected).

Fields of papers citing papers by Esther H. Chang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Esther H. Chang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Esther H. Chang. The network helps show where Esther H. Chang may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Esther H. Chang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Esther H. Chang Line = papers co-authored together Esther H. Chang links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	SMARCB1 Gene Therapy Using a Novel Tumor-Targeted Nanomedicine Enhances Anti-Cancer Efficacy in a Mouse Model of Atypical Teratoid Rhabdoid Tumors International Journal of Nanomedicine ·Sang Soo Kim,Manish Moghe,Antonina Rait,K. Donaldson,Joe B. Harford,Esther H. Chang	2024	2
2	A tumor‐targeting nanomedicine carrying the p53 gene crosses the blood–brain barrier and enhances anti‐PD‐1 immunotherapy in mouse models of glioblastoma International Journal of Cancer ·Sang Soo Kim,Joe B. Harford,Manish Moghe,Tiffani Slaughter,Caroline Doherty,Esther H. Chang	2019	51
3	Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma Cancer Letters ·Sang Soo Kim,Antonina Rait,Eric H. Kim,James DeMarco,Kathleen F. Pirollo,Esther H. Chang	2015	91
4	Nanomedicine: Past, present and future – A global perspective Biochemical and Biophysical Research Communications ·Esther H. Chang,Joe B. Harford,Michael A. W. Eaton,Patrick Boisseau,Admire Dube,Rose Hayeshi,Hulda Swai,Dong Soo Lee	2015	96
5	T-cell vaccines that elicit effective immune responses against HCV in chimpanzees may create greater immune pressure for viral mutation Vaccine ·Iryna Zubkova,You-kyung Choi,Esther H. Chang,Kathleen F. Pirollo,Tania K. Uren,Hisayoshi Watanabe,F B Wells,A. V. Kachko,K. Krawczyński,Marian Major	2009	26
6	Does a targeting ligand influence nanoparticle tumor localization or uptake? Trends in biotechnology ·Kathleen F. Pirollo,Esther H. Chang	2008	281
7	HER‐2‐Targeted Antisense Oligonucleotide Results in Sensitization of Head and Neck Cancer Cells to Chemotherapeutic Agents Annals of the New York Academy of Sciences ·Antonina Rait,Kathleen F. Pirollo,David Ulick,Kevin J. Cullen,Esther H. Chang	2003	26
8	Inhibitory effects of the combination of HER-2 antisense oligonucleotide and chemotherapeutic agents used for the treatment of human breast cancer Cancer Gene Therapy ·Antonina Rait,Kathleen F. Pirollo,Vladimir Rait,Jeffrey E. Krygier,Laiman Xiang,Esther H. Chang	2001	21
9	Tp53 gene therapy: a key to modulating resistance to anticancer therapies? Molecular Medicine Today ·Esther H. Chang,Kathleen F. Pirollo,Kerrie B. Bouker	2000	21
10	Comparative Gene Mapping in the Domestic Cat (Felis catus) Journal of Heredity ·Stephen J. O’Brien,S Cevario,Janice S. Martenson,Mary Ann Thompson,William G. Nash,Esther H. Chang,Jennifer A. Marshall Graves,James A. Spencer,Kyesoo Cho,Hajime Tsujimoto,Leslie A. Lyons	1997	41
11	Evidence Supporting a Signal Transduction Pathway Leading to the Radiation-Resistant Phenotype in Human Tumor Cells Biochemical and Biophysical Research Communications ·Kathleen F. Pirollo,Zhengmei Hao,Antonina Rait,Chong Wai Ho,Esther H. Chang	1997	61
12	p53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy Oncogene ·Kathleen F. Pirollo,Zhengmei Hao,Antonina Rait,Yng-Ju Jang,Willard E. Fee,Patricia C. Ryan,Ya‐Wen Chiang,Esther H. Chang	1997	103
13	Expression of the c-erbB-2 (Her-2/neu) Oncoprotein in Human Prostatic Carcinoma The Journal of Urology ·Eric J. Kuhn,Richard A. Kurnot,Isabell A. Sesterhenn,Esther H. Chang,Judd W. Moul	1993	127
14	Oncogenic Basis of Radiation Resistance Advances in cancer research ·Usha N. Kasid,Kathleen F. Pirollo,Anatoly Dritschilo,Esther H. Chang	1993	33
15	Infrequent RAS oncogene mutations in human prostate cancer The Prostate ·Judd W. Moul,Paul Friedrichs,Raymond S. Lance,Sheila M. Theune,Esther H. Chang	1992	74
16	Detection of RAS mutations in archival testicular germ cell tumors by polymerase chain reaction and oligonucleotide hybridization Genes Chromosomes and Cancer ·Judd W. Moul,Sheila M. Theune,Esther H. Chang	1992	34
17	Raf Involvement in the Simultaneous Genetic Transfer of the Radioresistant and Transforming Phenotypes International Journal of Radiation Biology ·Kathleen F. Pirollo,Rosa Garner,Song Yuan,Li Li,William A. Blattner,Esther H. Chang	1989	50
18	A fragment of the human c-ki-ras1 pseudogene (HGM9 gene symbol KRASIP), lacalized to 6p12–p11, detects 3 allele, RFLP Nucleic Acids Research ·Hélène Blanché,Esther H. Chang,J Dausset,Howard M. Cann	1988	4
19	Interferon- Induces Altered Oncogene Expression and Terminal Differentiation in A431 Cells Experimental Biology and Medicine ·Esther H. Chang,Jeanette Ridge,Ronald S. Black,Zhiqiang Zou,Taras Masnyk,P. Noguchi,Joe B. Harford	1987	21
20	Assignment of RAS proto-oncogenes in Chinese hamsters: implications for mammalian gene linkage conservation and neoplasia Cytogenetic and Genome Research ·Raymond L. Stallings,Brian D. Crawford,Roberta Black,Esther H. Chang	1986	7

About Esther H. Chang

Esther H. Chang is a scholar working on Biotechnology, Oncology and Virology, having authored 124 papers that have together received 9.6k indexed citations. Recurring topics across this work include RNA Interference and Gene Delivery (35 papers), Cancer-related Molecular Pathways (27 papers), Virus-based gene therapy research (24 papers), Cancer Research and Treatments (17 papers), Advanced biosensing and bioanalysis techniques (14 papers), Nanoparticle-Based Drug Delivery (10 papers), MicroRNA in disease regulation (9 papers) and DNA and Nucleic Acid Chemistry (8 papers). The work is most often cited by research in Oncology (3.1k citations), Cancer Research (1.5k citations) and Biomaterials (1.2k citations). Esther H. Chang has collaborated with scholars based in United States, Japan and Netherlands. Frequent co-authors include Kathleen F. Pirollo, Douglas R. Lowy, Edward M. Scolnick, Antonina Rait, Shiv Srivastava, Zhiqiang Zou, William A. Blattner, Robert A. Weinberg, Sang Soo Kim and Mark E. Furth. Their work appears in journals such as Nature, Science and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact